Ciphergen Names Diagnostics Division Vice President of Clinical and Medical Affairs
July 14 2004 - 5:15PM
PR Newswire (US)
Ciphergen Names Diagnostics Division Vice President of Clinical and
Medical Affairs FREMONT, Calif., July 14 /PRNewswire-FirstCall/ --
Ciphergen Biosystems, Inc. (NASDAQ:CIPH) announced today that Dr.
Eric Fung, M.D., Ph.D. has been promoted to the position of Vice
President, Clinical and Medical Affairs, in its newly formed
Diagnostics Division. In his new position, Dr. Fung will manage the
clinical and medical research that forms the basis of a major
clinical diagnostics business initiative by the company to develop
and commercialize Protein Molecular Diagnostics, based on the
ProteinChip(R) platform. In his new position, he will report to
Gail S. Page, President of Ciphergen's Diagnostics Division. "Dr.
Fung has played a key role in developing and managing our
diagnostic biomarker pipeline and fostering our collaborations with
key accounts such as Johns Hopkins Medical School, MD Anderson, and
Eastern Virginia Medical School over the last four years," stated
Gail S. Page, President of Ciphergen's Diagnostics Division. "His
combination of clinical and scientific experience has been a
critical factor in Ciphergen's success." Dr. Fung joined Ciphergen
in 2000 as a lead scientist in the newly formed Biomarker Discovery
Center(R) laboratories and managed many of Ciphergen's academic and
pharmaceutical collaborations. He was most recently Director of
Clinical Affairs. Prior to joining Ciphergen, Dr. Fung was a Howard
Hughes sponsored researcher at Stanford University, working under
Dr. Richard Scheller. Dr. Fung has anatomic pathology training from
Stanford Medical School, and obtained his M.D. and Ph.D. degree in
molecular neuroscience from the Johns Hopkins University School of
Medicine. He graduated with a BS in biology with honors from the
California Institute of Technology. Dr. Fung also currently holds
an Adjunct Assistant Professor position in the Department of
Pathology at the Johns Hopkins University School of Medicine.
Beginning in 2000, Ciphergen established the first of a series of
Biomarker Discovery Center(R) laboratories and established a major
collaboration with the Johns Hopkins University School of Medicine
with the intention of employing Ciphergen technology to discover
biomarkers and develop assays based on multi-biomarkers which might
have greater predictive power than single marker tests. While
Ciphergen is perhaps best noted for its diagnostic efforts in the
early detection in cancer, the company also has active discovery
programs underway in neurology, cardiovascular and infectious
disease, focused on a variety of clinical questions including
disease detection, treatment response, monitoring, classification
and prognosis. About Ciphergen Ciphergen's Biosystems Division
develops, manufactures and markets a family of ProteinChip(R)
Systems and services for clinical, research, and process proteomics
applications, as well as a broad range of bioseparations media for
protein purification and large scale production. ProteinChip
Systems enable protein discovery, characterization, identification
and assay development to provide researchers with predictive,
multi-marker assay capabilities and a better understanding of
biological function at the protein level. Ciphergen's Diagnostics
Division is dedicated to the discovery of protein biomarkers and
panels of biomarkers and their development into protein molecular
diagnostic tests that improve patient care; and to providing
collaborative R&D services through its Biomarker Discovery
Center(R) laboratories for biomarker discovery for new diagnostic
tests as well as pharmacoproteomic services for improved drug
toxicology, efficacy and theranostic assays. Additional information
about Ciphergen can be found at http://www.ciphergen.com/. Safe
Harbor Statement Note Regarding Forward-Looking Statements: For
purposes of the Private Securities Litigation Reform Act of 1995
(the "Act"), Ciphergen disclaims any intent or obligation to update
these forward-looking statements, and claims the protection of the
Safe Harbor for forward-looking statements contained in the Act.
Examples of such forward-looking statements include statements
regarding the use of ProteinChip technology to discover useful
protein biomarkers that can act as novel drug targets or disease
markers, develop and commercialize clinical diagnostics that
improve patient care, the ability to provide services that lead to
improved toxicology assays and diagnostic assays, and statements
regarding our Diagnostics Division. Actual results may differ
materially from those projected in such forward-looking statements
due to various factors, including the ProteinChip technology's
ability to validate and/or develop protein biomarkers as novel drug
targets, diagnostic or toxicology assays, and the Company's ability
to successfully commercialize such tests. Investors should consult
Ciphergen's filings with the Securities and Exchange Commission,
including its Form 10-Q dated May 10, 2004 and amended May 20,
2004, for further information regarding these and other risks of
the Company's business. NOTE: Ciphergen, ProteinChip, Biomarker
Discovery Center and BioSepra are registered trademarks of
Ciphergen Biosystems, Inc. DATASOURCE: Ciphergen Biosystems, Inc.
CONTACT: investors, Sue Carruthers of Ciphergen Biosystems, Inc.,
+1-510-505 2297 Web site: http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From May 2024 to Jun 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2023 to Jun 2024